SGN-35T
- Generic Name
- SGN-35T
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1
Recruiting
- Conditions
- Lymphoma, Large-Cell, AnaplasticLymphoma, Non-HodgkinLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousHodgkin DiseaseLymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 150
- Registration Number
- NCT06120504
- Locations
- 🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸University of Miami Hospital and Clinics - Lennar, Coral Gables, Florida, United States
🇺🇸University of Miami Hospital And Clinics, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath